Absorption Systems rolls-out preclinical device testing service
The US firm introduced an extensively renovated surgical suite for preclinical medical device testing at its facility in San Diego, explaining that the move is in response to growing demand for contract device analysis.
Absorption said that its 1,100 sqft lab offers clients a broad range of services, experimental models and surgical capabilities, including C-arm high-resolution digital fluoroscopy anesthesia systems and an observation room.
CEO Patrick Dentinger discussed the Absorption’s move into preclinical device testing, explaining that the new surgical suite will help move clients devices from the concept stage through to regulatory filing.
“We expect that our new facility, coupled with our renowned customer service, will factor into medical device manufacturers’ decisions when selecting Absorption Systems for testing.”
New drug metabolism assays
Despite the new offering, Absorption also showed signs it will focus on preclinical drug candidate testing, particularly in absorption, distribution, metabolism and excretion (ADME) testing for small-molecule pharmaceuticals which is its core offering.
On December 2, the firm introduced a raft of new drug metabolism assays designed to support the pharmaceutical R&D process, from early-stage discovery through late-stage clinical development.
At the time the firm said the new test will “provide researchers with a more comprehensive picture of the role that metabolites, which are generally associated with the body’s detoxification process, play in drug safety.
“If metabolites are not produced by and eliminated from the body in a timely fashion, a drug’s active ingredients can accumulate and increase the potential for adverse reactions.
The new products cover a wide range of metabolic analyses, such as biomimetic oxidation, metabolite ID and time-dependent inhibition.
